Skip to main content
Erschienen in: Clinical and Translational Oncology 2/2017

04.08.2016 | Research Article

Demand for radiotherapy in Spain

verfasst von: A. Rodríguez, J. M. Borrás, J. López-Torrecilla, M. Algara, A. Palacios-Eito, A. Gómez-Caamaño, L. Olay, P. C. Lara

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Aim

Assessing the demand for radiotherapy in Spain based on existing evidence to estimate the human resources and equipment needed so that every person in Spain has access to high-quality radiotherapy when they need it.

Material and methods

We used data from the European Cancer Observatory on the estimated incidence of cancer in Spain in 2012, along with the evidence-based indications for radiotherapy developed by the Australian CCORE project, to obtain an optimal radiotherapy utilisation proportion (OUP) for each tumour.

Results

About 50.5 % of new cancers in Spain require radiotherapy at least once over the course of the disease. Additional demand for these services comes from reradiation therapy and non-melanoma skin cancer. Approximately, 25–30 % of cancer patients with an indication for radiotherapy do not receive it due to factors that include access, patient preference, familiarity with the treatment among physicians, and especially resource shortages, all of which contribute to its underutilisation.

Conclusions

Radiotherapy is underused in Spain. The increasing incidence of cancer expected over the next decade and the greater frequency of reradiations necessitate the incorporation of radiotherapy demand into need-based calculations for cancer services planning.
Literatur
1.
Zurück zum Zitat Lievens Y, Borras JM, Grau C. Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology. Acta Oncol. 2015;54:1275–84.CrossRefPubMed Lievens Y, Borras JM, Grau C. Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology. Acta Oncol. 2015;54:1275–84.CrossRefPubMed
3.
Zurück zum Zitat Borras JM, Lievens Y, Grau C. The need for radiotherapy in Europe in 2020: not only data but also a cancer plan. Acta Oncol. 2015;54:1268–74.CrossRefPubMed Borras JM, Lievens Y, Grau C. The need for radiotherapy in Europe in 2020: not only data but also a cancer plan. Acta Oncol. 2015;54:1268–74.CrossRefPubMed
4.
Zurück zum Zitat Delaney G, Jacob S, Featherstone C, Barton MB. The role of radiotherapy in cáncer treatment. Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–37.CrossRefPubMed Delaney G, Jacob S, Featherstone C, Barton MB. The role of radiotherapy in cáncer treatment. Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–37.CrossRefPubMed
5.
Zurück zum Zitat Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75:355–65.CrossRefPubMed Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75:355–65.CrossRefPubMed
6.
Zurück zum Zitat Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney G. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014;112:140–4.CrossRefPubMed Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney G. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014;112:140–4.CrossRefPubMed
7.
Zurück zum Zitat Grau C, Dofourney N, Malicki J, Dunscombe P, Borras JM, Coffey M, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:155–64.CrossRefPubMed Grau C, Dofourney N, Malicki J, Dunscombe P, Borras JM, Coffey M, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:155–64.CrossRefPubMed
8.
Zurück zum Zitat Lievens Y, Defourny N, Coffey M, Borras JM, Dunscombe P, Slotman B, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:178–86.CrossRefPubMed Lievens Y, Defourny N, Coffey M, Borras JM, Dunscombe P, Slotman B, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112:178–86.CrossRefPubMed
9.
Zurück zum Zitat Borras JM, Lievens Y, Dunscombe P, et al. The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO HERO analysis. Radiother Oncol. 2015;116:38–44.CrossRefPubMed Borras JM, Lievens Y, Dunscombe P, et al. The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO HERO analysis. Radiother Oncol. 2015;116:38–44.CrossRefPubMed
10.
Zurück zum Zitat Poortmans P, Valentini V, Lievens Y. Expanding Global access to radiotherapy: the European Society for Radiotherapy and Oncology perspective. Lancet Oncol. 2015;16:1149.CrossRef Poortmans P, Valentini V, Lievens Y. Expanding Global access to radiotherapy: the European Society for Radiotherapy and Oncology perspective. Lancet Oncol. 2015;16:1149.CrossRef
11.
Zurück zum Zitat Steliarova-Foucher E, O’Callaghan M, Ferlay J, Massuyer E, Rosso S, Forman D, et al. The European cancer observatory: a new data resource. Eur J Cancer. 2015;51:1131–43.CrossRefPubMed Steliarova-Foucher E, O’Callaghan M, Ferlay J, Massuyer E, Rosso S, Forman D, et al. The European cancer observatory: a new data resource. Eur J Cancer. 2015;51:1131–43.CrossRefPubMed
15.
Zurück zum Zitat Tyldesley S, Boyd C, Schulze K, Walter H, Mackillop W. Estimating the need for radiotherapy for lung cancer: an evidence-based epidemiological approach. Int J Radiat Oncol Biol Phys. 2001;49:973–85.CrossRefPubMed Tyldesley S, Boyd C, Schulze K, Walter H, Mackillop W. Estimating the need for radiotherapy for lung cancer: an evidence-based epidemiological approach. Int J Radiat Oncol Biol Phys. 2001;49:973–85.CrossRefPubMed
16.
Zurück zum Zitat Jena R, Round C, Mee T, Kirkby NF, Cooper T, Hoskin P, Jena R. The Malthus model: a new tool for estimating radiotherapy demand at local level. Clin Oncol. 2012;23:1–3.CrossRef Jena R, Round C, Mee T, Kirkby NF, Cooper T, Hoskin P, Jena R. The Malthus model: a new tool for estimating radiotherapy demand at local level. Clin Oncol. 2012;23:1–3.CrossRef
17.
Zurück zum Zitat Wong K, Delaney G, Barton MB. Evidence-based optimal number of radiotherapy fractions for cancer: a useful tool to estimate radiotherapy demand. Radiother Oncol. 2015;116(2):174–8.CrossRefPubMed Wong K, Delaney G, Barton MB. Evidence-based optimal number of radiotherapy fractions for cancer: a useful tool to estimate radiotherapy demand. Radiother Oncol. 2015;116(2):174–8.CrossRefPubMed
18.
Zurück zum Zitat Ingham Institute for Applied Medical Research (IIAMR)- Collaboration for Cancer Outcomes Research and Evaluation (CCORE). Review of optimal radiotherapy utilisation rates. CCORE report; 2013. Available from: tinyurl.com/pwkua34 (accessed 26-11-2014). Ingham Institute for Applied Medical Research (IIAMR)- Collaboration for Cancer Outcomes Research and Evaluation (CCORE). Review of optimal radiotherapy utilisation rates. CCORE report; 2013. Available from: tinyurl.com/pwkua34 (accessed 26-11-2014).
19.
Zurück zum Zitat Van de Werf E, Verstraete J, Lievens Y. The cost of radiotherapy in a decade of technology evolution. Radiother Oncol. 2012;102:148–53.CrossRefPubMed Van de Werf E, Verstraete J, Lievens Y. The cost of radiotherapy in a decade of technology evolution. Radiother Oncol. 2012;102:148–53.CrossRefPubMed
20.
Zurück zum Zitat Slotman B, Vos P. Planning of radiotherapy capacity and productivity. Radiother Oncol. 2013;106:266–70.CrossRefPubMed Slotman B, Vos P. Planning of radiotherapy capacity and productivity. Radiother Oncol. 2013;106:266–70.CrossRefPubMed
21.
Zurück zum Zitat Barton MB, Allen S, Delaney GP, et al. Patterns of retreatment by radiotherapy. Clinical Oncol. 2014;26:611–8.CrossRef Barton MB, Allen S, Delaney GP, et al. Patterns of retreatment by radiotherapy. Clinical Oncol. 2014;26:611–8.CrossRef
22.
Zurück zum Zitat Popovic M, den Hartog M, Zhang L, et al. Review of international patterns of practice for the treatment of painful bone metastases with palliative radiotherapy from 1993 to 2013. Radiother Oncol. 2014;111:11–7.CrossRefPubMed Popovic M, den Hartog M, Zhang L, et al. Review of international patterns of practice for the treatment of painful bone metastases with palliative radiotherapy from 1993 to 2013. Radiother Oncol. 2014;111:11–7.CrossRefPubMed
23.
Zurück zum Zitat Esco R, Palacios A, Pardo J, et al. Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources. Int J Radiat Oncol Biol Phys. 2003;56(2):319–27.CrossRefPubMed Esco R, Palacios A, Pardo J, et al. Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources. Int J Radiat Oncol Biol Phys. 2003;56(2):319–27.CrossRefPubMed
Metadaten
Titel
Demand for radiotherapy in Spain
verfasst von
A. Rodríguez
J. M. Borrás
J. López-Torrecilla
M. Algara
A. Palacios-Eito
A. Gómez-Caamaño
L. Olay
P. C. Lara
Publikationsdatum
04.08.2016
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 2/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1525-x

Weitere Artikel der Ausgabe 2/2017

Clinical and Translational Oncology 2/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.